- Home
- LNKB vs AURA Comparison
LNKB vs AURA Comparison
Compare LNKB & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LNKB | AURA |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 327.5M | 419.5M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LNKB | AURA |
|---|---|---|
| Price | $8.89 | $7.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 82.3K | ★ 279.3K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | ★ 26.76 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $186,504,000.00 | N/A |
| Revenue This Year | $10.18 | N/A |
| Revenue Next Year | $9.33 | N/A |
| P/E Ratio | $9.82 | ★ N/A |
| Revenue Growth | ★ 11.29 | N/A |
| 52 Week Low | $6.30 | $4.73 |
| 52 Week High | $9.59 | $7.48 |
Technical Indicators
Market Signals| Indicator | LNKB | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 62.68 | 67.44 |
| Support Level | $7.01 | $5.94 |
| Resistance Level | $9.02 | $7.44 |
| Average True Range (ATR) | 0.20 | 0.33 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 97.27 | 95.79 |
Price Performance
Historical ComparisonAbout LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About AURA Aura Biosciences Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.